CME in Minutes: Education in Oncology & Hematology

Author: Answers in CME

Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Oncology & Hematology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for oncologists and hematologists to cover the diagnosis, staging, treatment, follow-up, and clinical management of tumors and hematological malignancies. Earning your CME/CE credits has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.
Be a guest on this podcast

Language: en-us

Genres: Health & Fitness, Life Sciences, Medicine, Science

Contact email: Get it

Feed URL: Get it

iTunes ID: Get it

Get all podcast data

Listen Now...

Navigating Urologic Cancer Care Across the Map: Getting up to Speed on the Latest Systemic Therapies for Renal Cell Carcinoma and Advanced Urothelial Carcinoma
Friday, 10 April, 2026

Please visit answersincme.com/860/240201307-replay1 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Normand Blais, MD, MSc; Aly-Khan A. Lalani, MD, FRCPC; Wassim Kassouf, MD; and Eleftherios Soleas, PhD. In this activity, experts in managing urothelial carcinoma and renal cell carcinoma (RCC) from across Canada discuss evidence-based strategies for integrating the latest systemic therapies into practice to optimize outcomes for patients with advanced urothelial carcinoma and resected/advanced RCC, with insights into regional practice considerations. Upon completion of this activity, participants should be better able to: Incorporate the latest evidence on frontline combination regimens into treatment planning for advanced urothelial carcinoma; Identify strategies to optimally incorporate adjuvant immunotherapy into treatment plans for eligible patients with early-stage renal cell carcinoma (RCC); and Evaluate how current evidence and guidelines may inform optimal sequencing of therapies in later-line settings for patients with advanced RCC.